PTGX

Over the past six months, Protagonist Therapeutics' stock was significantly impacted by the FDA approvals of ICOTYDE™ in March 2026 and MIMRYLO™ in August 2026, which triggered substantial milestone payments and contributed to a Q2 2026 profit of US$162.8 million. In September 2026, the company announced a $300 million share repurchase program. Other events included the reporting of Q2 2026 financial results and corporate updates in August 2026, the removal of the FDA clinical hold on the Rusfertide Clinical Development Program in October 2025, and collaboration agreements with Janssen Biotech, Inc. in October and July 2025. The stock price showed significant growth, increasing by 153.82% between September 2025 and September 2026, and by 66.0% year-to-date as of September 2026, reaching an all-time high of $160.81 USD in August 2026.